{"id":921764,"date":"2025-12-22T07:04:07","date_gmt":"2025-12-22T12:04:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/"},"modified":"2025-12-22T07:04:07","modified_gmt":"2025-12-22T12:04:07","slug":"pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/","title":{"rendered":"Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved"},"content":{"rendered":"
\n

HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) — Pluri, Inc. (\u201cPluri\u201d, the \u201cCompany\u201d, \u201cwe\u201d or \u201cus\u201d) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024<\/a> with Remedy Cell Ltd. (\u201cRemedy Cell\u201d), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.<\/p>\n

Under the ongoing collaboration Remedy Cell\u2019s personnel, along with Pluri\u2019s Contract Development and Manufacturing Organization (\u201cCDMO\u201d) division (PluriCDMO\u2122), have successfully completed the full implementation of Remedy Cell\u2019s proprietary manufacturing process into Pluri\u2019s state-of-the-art Good Manufacturing Practice (\u201cGMP\u201d) facility, conducted GMP training and qualification for the Remedy Cell manufacturing team, executed engineering runs to confirm process robustness and scalability, and manufactured several clinical-grade batches of Remedy Cell\u2019s lead candidate. These batches are intended for use in Remedy Cell\u2019s initial Phase 1b clinical trial, representing a major step in its clinical development. This achievement reflects the strong synergy between Remedy Cell\u2019s innovative therapeutic platform and Pluri\u2019s advanced manufacturing facilities.<\/p>\n

The completion of these activities demonstrates PluriCDMO\u2122\u2019s potential to serve complex cell-derived and cell-free processes with consistent, scalable, and regulatory-compliant manufacturing solutions. For Remedy Cell, this milestone marks tangible progress on its path toward clinical development and the realization of its mission to bring secretome-based therapies to patients with fibrotic diseases.<\/p>\n

Building on this success, Pluri and Remedy Cell are now broadening the scope of their collaboration. PluriCDMO\u2122 will continue to provide additional manufacturing and process-development support as Remedy Cell advances its clinical and pre-commercial programs. The expanded activity underscores the productive partnership between the teams and their shared commitment to advancing next-generation, cell-free biologics that address significant unmet medical needs.<\/p>\n

\u201cWorking with Pluri has been highly productive,\u201d said Ayelet Dilion-Mashiah, Chief Executive Officer of Remedy Cell. \u201cPluri\u2019s expertise and professionalism have been invaluable in helping us reach this critical milestone. Completing our clinical-grade manufacturing and preparing for our first clinical trial is a defining achievement for Remedy Cell, and we look forward to continuing this productive partnership.\u201d<\/p>\n

\n \u201cWe are proud to continue strengthening our agreement with Remedy Cell, working together to achieve every project milestone \u2014 from technology implementation and engineering runs to the successful manufacture of clinical-grade batches for their first human trial,\u201d said Yaky Yanay, Chief Executive Officer and President of Pluri. \u201cRemedy Cell\u2019s scientific approach is highly innovative, and it has been a privilege to contribute to their progress. This success further positions PluriCDMO\u2122 as a trusted partner for companies developing complex, cell-derived therapies.\u201d<\/span>\n <\/p>\n

\n About Pluri Inc.<\/strong>
\n
Pluri\u2122 is a biotechnology company pioneering mass-scale cell expansion and biofarming. Using its patented, proprietary 3D cell expansion platform, Pluri develops scalable, consistent, and cost-efficient cell-based solutions. The Company drives innovation in regenerative medicine, foodtech, agtech, and offers CDMO services. With two decades of experience, a strong intellectual property portfolio and its collaborative network of ventures, Pluri accelerates breakthroughs that address global challenges such as sustainable food production, healthcare, and climate resilience. To learn more, visit www.pluri-biotech.com<\/u><\/a> or follow Pluri on LinkedIn<\/u><\/a> and X<\/u><\/a>.<\/p>\n

\n About <\/strong>
\n PluriCDMO<\/strong>\u2122
Pluri launched its CDMO division<\/u><\/a> in January 2024, leveraging its proprietary knowledge, cutting-edge technology and cell therapy production facility on behalf of clients. PluriCDMO\u2122 clients gain access to Pluri’s state-of-the-art GMP facilities, and to Pluri’s patented bioreactor system, which enables cell expansion at mass scale via a fully controlled, automated and validated process. For more information visit www.pluri-biotech.com\/cdmo<\/a> or contact CDMO@Pluri-biotech.com<\/a><\/p>\n

\n About Remedy<\/strong>
\n Cell<\/strong>
\n Ltd.<\/strong>
\n
Remedy Cell Ltd., is a clinical stage biopharmaceutical company revolutionising fibrotic disease treatment with cell-derived, cell-free breakthrough therapies. The company\u2019s proprietary Activated Remedy Cell Secretome (ARcS) platform delivers multi-target, pro-regenerative solutions for complex fibrotic conditions. The company\u2019s lead product, RC-0315, a first-in-class activated MSC-derived secretome therapy for of Idiopathic Pulmonary Fibrosi (\u201cIPF\u201d), has shown in definitive preclinical studies the potential to repair lung tissue and restore function. IPF is a fatal, highly complex and progressive interstitial lung disease affecting approximately 3 million people worldwide. With a median survival of only 2-5 years post-diagnosis.\u00a0Despite the considerable impact of these diseases, current therapeutic options remain limited in both efficacy and scope, creating an urgent need for innovative approaches. To learn more, visit www.remedycell.com<\/a> or follow Remedy Cell on LinkedIn<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses the expectation that the clinical-grade batches of Remedy Cell\u2019s lead candidate will be used in Remedy Cell\u2019s initial Phase 1 clinical trial; the belief that the completion of the listed activities reflects PluriCDMO\u2019s proven ability to serve complex cell-derived and cell-free processes with consistent, scalable, and regulatory-compliant manufacturing solutions; Remedy Cell\u2019s ability to progress on its path toward clinical development and the realization of its mission to bring secretome-based therapies to patients with fibrotic diseases; Pluri and Remedy Cell\u2019s ability to broaden the scope of their agreement, including Pluri\u2019s ability to provide additional manufacturing and process-development support, and Remedy Cell\u2019s ability to advance its clinical and pre-commercial programs; and the expectation that Pluri\u2019s and Remedy Cell\u2019s underscore the productive partnership between the teams and their shared commitment to advancing next-generation, cell-free biologics that address significant unmet medical needs. . These forward-looking statements and their implications are based on the current expectations of Pluri\u2019s and Remedy Cell\u2019s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in consumer preferences or aesthetics industry trends; Pluri or each of its subsidiaries may encounter delays or obstacles in the launch, development, manufacturing, or commercialization of its food\/agtech products; regulatory hurdles in new markets; the efficacy or safety of cell-derived products may not meet expectations; shifts in strategic priorities by Pluri or its partners\/collaborators, including these global food and agtech companies; challenges in marketing or brand alignment; intellectual property risks; unforeseen scientific or operational difficulties; inability to attract or retain key personnel; and competitive pressures that could impact market adoption or pricing. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri\u2019s reports filed from time to time with the Securities and Exchange Commission.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n

Investors: investor.relations@pluri-biotech.com<\/a>
U.S. Media: Berry Brady at berry@quantum-corp.com<\/a>
Israel Media: Shachar Yental at\u00a0shacharye@gitam.co.il<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) — Pluri, Inc. (\u201cPluri\u201d, the \u201cCompany\u201d, \u201cwe\u201d or \u201cus\u201d) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. (\u201cRemedy Cell\u201d), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions. Under the ongoing collaboration Remedy Cell\u2019s personnel, along with Pluri\u2019s Contract Development and Manufacturing Organization (\u201cCDMO\u201d) division (PluriCDMO\u2122), have successfully completed the full implementation of Remedy Cell\u2019s proprietary manufacturing process into Pluri\u2019s state-of-the-art Good Manufacturing Practice (\u201cGMP\u201d) facility, conducted GMP training and qualification for the Remedy Cell manufacturing team, executed engineering runs to confirm process … <\/p>\n

Continue reading “Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-921764","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) — Pluri, Inc. (\u201cPluri\u201d, the \u201cCompany\u201d, \u201cwe\u201d or \u201cus\u201d) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. (\u201cRemedy Cell\u201d), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions. Under the ongoing collaboration Remedy Cell\u2019s personnel, along with Pluri\u2019s Contract Development and Manufacturing Organization (\u201cCDMO\u201d) division (PluriCDMO\u2122), have successfully completed the full implementation of Remedy Cell\u2019s proprietary manufacturing process into Pluri\u2019s state-of-the-art Good Manufacturing Practice (\u201cGMP\u201d) facility, conducted GMP training and qualification for the Remedy Cell manufacturing team, executed engineering runs to confirm process … Continue reading "Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-22T12:04:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNTg3MSM3MzMyNzIyIzIwMTc1OTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved\",\"datePublished\":\"2025-12-22T12:04:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\\\/\"},\"wordCount\":1166,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNTg3MSM3MzMyNzIyIzIwMTc1OTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\\\/\",\"name\":\"Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNTg3MSM3MzMyNzIyIzIwMTc1OTY=\",\"datePublished\":\"2025-12-22T12:04:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNTg3MSM3MzMyNzIyIzIwMTc1OTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxNTg3MSM3MzMyNzIyIzIwMTc1OTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/","og_locale":"en_US","og_type":"article","og_title":"Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved - Market Newsdesk","og_description":"HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) — Pluri, Inc. (\u201cPluri\u201d, the \u201cCompany\u201d, \u201cwe\u201d or \u201cus\u201d) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. (\u201cRemedy Cell\u201d), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions. Under the ongoing collaboration Remedy Cell\u2019s personnel, along with Pluri\u2019s Contract Development and Manufacturing Organization (\u201cCDMO\u201d) division (PluriCDMO\u2122), have successfully completed the full implementation of Remedy Cell\u2019s proprietary manufacturing process into Pluri\u2019s state-of-the-art Good Manufacturing Practice (\u201cGMP\u201d) facility, conducted GMP training and qualification for the Remedy Cell manufacturing team, executed engineering runs to confirm process … Continue reading \"Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-22T12:04:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNTg3MSM3MzMyNzIyIzIwMTc1OTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved","datePublished":"2025-12-22T12:04:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/"},"wordCount":1166,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNTg3MSM3MzMyNzIyIzIwMTc1OTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/","name":"Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNTg3MSM3MzMyNzIyIzIwMTc1OTY=","datePublished":"2025-12-22T12:04:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNTg3MSM3MzMyNzIyIzIwMTc1OTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxNTg3MSM3MzMyNzIyIzIwMTc1OTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pluri-and-remedy-cell-expand-collaboration-successful-engineering-runs-and-clinical-grade-manufacturing-achieved\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/921764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=921764"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/921764\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=921764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=921764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=921764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}